Skip to main navigation Skip to search Skip to main content

Transthyretin sequesters amyloid β protein and prevents amyloid formation

  • Alexander L. Schwarzman
  • , Luisa Gregori
  • , Michael P. Vitek
  • , Sergey Lyubski
  • , Warren J. Strittmatter
  • , Jan J. Enghilde
  • , Ramaninder Bhasin
  • , Josh Silverman
  • , Karl H. Weisgraber
  • , Patricia K. Coyle
  • , Michael G. Zagorski
  • , Joseph Talafous
  • , Moises Eisenberg
  • , Ann M. Saunders
  • , Allen D. Roses
  • , Dmitry Goldgaber
  • Stony Brook University
  • Massachusetts Institute of Technology
  • Duke University
  • University of California at San Francisco
  • Case Western Reserve University

Research output: Contribution to journalArticlepeer-review

385 Scopus citations

Abstract

The cardinal pathological features of Alzheimer disease are depositions of aggregated amyloid β protein (Aβ) in the brain and cerebrovasculature. However, the Aβ is found in a soluble form in cerebrospinal fluid in healthy individuals and patients with Alzheimer disease. We postulate that sequestration of Aβ precludes amyloid formation. Failure to sequester Aβ in Alzheimer disease may result in amyloidosis. When we added Aβ to cerebrospinal fluid of patients and controls it was rapidly sequestered into stable complexes with transthyretin. Complexes with apolipoprotein E, which has been shown to bind Aβ in vitro, were not observed in cerebrospinal fluid. Additional in vitro studies showed that both purified transthyretin and apolipoprotein E prevent amyloid formation.

Original languageEnglish
Pages (from-to)8368-8372
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume91
Issue number18
DOIs
StatePublished - Aug 30 1994

Keywords

  • sequestration

Fingerprint

Dive into the research topics of 'Transthyretin sequesters amyloid β protein and prevents amyloid formation'. Together they form a unique fingerprint.

Cite this